Incannex Healthcare, Inc. is a biotech company, which engages in developing cannabinoid and psychedelic compound medicines. It focuses on the research and development for medicinal cannabis pharmaceutical products and psychedelic medicine therapies for treatment of a range of indications. The company was founded on July 5, 2023 and is headquartered in Norwest, Australia.
相关临床试验
6
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
3
50.0%
招募中
1
16.7%
暂停
1
16.7%
终止
1
16.7%
暂无批准数据
- Incannex Healthcare has entered a 50:50 joint venture with Mind Medicine Australia to launch a psychedelic-assisted therapies clinic in Melbourne, targeting PTSD and treatment-resistant depression. - The new entity, Mind Medicine Australia Clinics, will provide integrated services including clinical operations, governance, medicine supply, and clinician training to expand treatment access. - The updated clinic model is expected to reduce costs and more than triple service capacity, with patient intake beginning shortly in response to strong early demand. - Mind Medicine Australia successfully led the world's first regulatory rescheduling of psilocybin and MDMA for controlled clinical use in Australia in 2023.
- Incannex Healthcare has entered a binding agreement to cancel 172 million Series A Warrants for $12.2 million, eliminating up to 347.2 million shares from potential dilution when combined with earlier cancellations. - The strategic move comes ahead of July 2025 topline results from the Phase 2 RePOSA trial of IHL-42X, a potential first-in-class oral treatment for obstructive sleep apnea. - IHL-42X, combining dronabinol and acetazolamide, previously demonstrated a 51% reduction in Apnea-Hypopnea Index in Australian Phase 2 trials and targets a condition with no current FDA-approved drug therapy. - The warrant cancellation strengthens Incannex's capital structure as the company approaches one of its most important clinical data readouts in company history.
- Incannex Healthcare has appointed sleep medicine expert Dr. Alison Wimms to their newly formed IHL-42X Obstructive Sleep Apnea Clinical Advisory Board, strengthening their clinical development expertise. - IHL-42X, a novel oral combination of acetazolamide and dronabinol, demonstrated promising results in Phase 2 trials with up to 51% reduction in Apnea-Hypopnea Index. - The company is advancing a global Phase 2/3 'RePOSA' clinical trial, with top-line results from the U.S. Phase 2 portion expected in first half of 2025.
- Incannex Healthcare's IHL-42X, a combination of dronabinol and acetazolamide, demonstrated bioavailability in a PK study, confirming delivery of both drugs. - The PK profile of IHL-42X was similar to reference listed drugs, potentially allowing leveraging of existing safety data for FDA 505(b)(2) application. - The IHL-42X pharmacokinetic results will inform the analysis of the ongoing Phase 2/3 RePOSA trial data in obstructive sleep apnea patients. - The study reported excellent safety and tolerability for IHL-42X, with no serious adverse events, supporting its further development.
- Incannex Healthcare reported positive Phase 2 results for PSX-001 in treating generalized anxiety disorder (GAD), showing significant anxiety reduction with synthetic psilocybin and psychotherapy. - Dosing has commenced in the Phase 2/3 RePOSA trial of IHL-42X for obstructive sleep apnea (OSA), with Phase 2 results expected in the first half of 2025. - The FDA cleared Incannex's IND application for PsiGAD2, a Phase 2b trial of PSX-001, to further evaluate its efficacy and safety in GAD patients. - Strategic financing with Arena Investors may provide Incannex up to $59.0 million to support clinical trials and general corporate purposes.
- Incannex Healthcare has secured a financing agreement with Arena Investors for up to $60 million to advance its clinical-stage drug candidates. - The financing includes $10 million in secured convertible notes and a $50 million equity line of credit with Arena Business Solutions. - Incannex will use the funds to support ongoing clinical trials for IHL-42X, PsiGAD, and IHL-675A, and for general corporate purposes. - The agreement provides an initial funding tranche of $3.33 million, with options for two additional tranches totaling up to $6.67 million.
- Reunion Neuroscience secured $103 million in Series A funding led by MPM Capital and Novo Holdings to advance RE104, a novel psychedelic treatment for postpartum depression. - RE104 is a synthetic prodrug of 4-OH-DiPT that produces psychedelic effects similar to psilocybin but with a significantly shorter duration of 3-4 hours compared to traditional psychedelics. - The company has initiated the RECONNECT Phase 2 clinical trial enrolling women within 12 months postpartum with moderate to severe depression, with results expected by Q2 next year. - The shorter treatment duration addresses FDA safety concerns by requiring only half a day in clinic compared to up to 12 hours for other psychedelics, potentially improving treatment accessibility.
